• Switch off the underlying key mechanistic events responsible for angiogenesis & metastasis (the deadly spread of cancer to other organs);
• Have no inherent toxicity, resulting in minimal side effects, if any;
• Act in the extracellular space – so that delivery to their site of action is unproblematic;
• Have little likelihood of causing drug resistance; and
• Have broad-spectrum activity against solid tumors.

To achieve these goals, Ångstrom is combining its extraordinary capability in creative drug design and discovery with the drug development infrastructures of large established pharmaceutical companies. To this end, the Company is negotiating joint ventures and strategic partnerships on a world-wide basis.

 Return to Home page

What's New - Management - Advisory Board - Drug Programs

Patents - Publications - Press Releases - Contact Us - Career Opportunities